Home Magazines Editors-in-Chief FAQs Contact Us

Screening for hydroxychloroquine maculopathy


Advances in Ophthalmology & Visual System
Emad Selim,1 Soad Elsawy,2 Sanjeev Verma,1 Noha Mouselhy,3 Rehab Auf4

PDF Full Text

Abstract

Introduction: Hydroxychloroquine (HCQ) is an immunosuppressant widely used by rheumatologists in treatment of Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) and other conditions.
 
Methods: Literature review on reasons why HCQ is commonly prescribed, its side effects and when it is practical to screen for them and what happen if those side effects develop.
 
Conclusion: Hydroxychloroquine is a disease modified medicine used in rheumatologic diseases. Since retinal toxicity is normally irreversible and progressive even after cessation of medicine, it essential to screen for early feature of retinal toxicity.

Keywords

chloroquine, hydroxychloroquine, maculopathy, rheumatoid arthritis, systemic lupus erythematosus, DMARMs

Testimonials